Protocol Ledger

NCT06547216 · Phase II · ACTIVE NOT RECRUITING

Phase 2 Open-label Extension Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD)

Interventional Phase II clinical trial protocol NCT06547216 sponsored by Avidity Biosciences in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2024-07-25 Enrollment: 84 participants (ESTIMATED) Federal Source: clinicaltrials.gov/study/NCT06547216
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)84 participants (ESTIMATED)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06547216
Protocol FieldVerified Registry Value
NCT IdentifierNCT06547216
Consolidated Lead SponsorAvidity Biosciences
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment84 participants (ESTIMATED)
Registered Start Date2024-07-25
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI